Defining the genetic landscape of nanophthalmos and the role of MYRF

确定纳米眼球的遗传图景和MYRF的作用 摘要： 小眼球是一系列疾病的一部分，其特征是小眼睛和由此产生的高度远视。它 常合并闭角型青光眼、斜视、弱视以及浆液性视网膜和脉络膜。 分队。这种疾病的发病机制尚不清楚，但遗传因素被认为是一种 强有力的贡献者。我已经确定了一种新的人类遗传性纳米眼球疾病基因，髓鞘调节基因 因子(MYRF)，这也会导致小鼠视网膜变性和视网膜色素上皮(RPE)破坏。 该基因编码一种多效性转录因子，与一种多系统紊乱有关。 以心脏、泌尿生殖系统缺陷和高度远视为特征。我的建议的主要目标是：(I)确定 MYRF在眼睛中的分子靶点；(Ii)定义MYRF被破坏导致 人类疾病和RPE功能障碍；以及(Iii)确定高血压病发病机制的新基因因素 远视。我的总体假设是，MYRF是RPE分化的主要调节者， 而MYRF关键下游靶点的破坏也通过破坏RPE而导致纳米眼球 结构和/或功能。这一假设将通过以下方式检验：(I)确定MYRF的分子靶标 通过单细胞RNA测序和切割和运行测序；以及(Ii)确定临床和遗传学 高度远视和小眼球家系的异质性。我的长期目标是成为一名 专注于识别和治疗遗传性眼病的独立临床医生研究员，以及 了解分子发病机制。为了促进这一目标，我组建了一个导师团队，并 具有相关专业知识的合作者；该团队包括一名发育遗传学家、一名眼科医生 临床医生、科学家、医学遗传学家、基因组学和生物信息学专家。我和我的导师们 制定了一项系统的培训计划，重点是授课和实践经验。和这支队伍一起 和强大的制度环境，我将在发育生物学、生物信息学和基因组学方面进行培训， 这些都是我专业发展和完成这项提案所必需的。这份职业 发展轨迹将使我发展成为眼科遗传学领域的领先临床医生和科学家，并且 在我的临床实践和基础科学研究之间提供了直接的联系。它还将为我提供 完成完整的基因发现周期的技能，这可能对患者护理有直接影响。这 该提案将导致对调节RPE发育的新途径的洞察，并识别可 调节眼睛生长，这将为未来的研究建立一个关键的新领域。

Defining the genetic landscape of nanophthalmos and the role of MYRF ABSTRACT: Nanophthalmos is part of a spectrum of disorders characterized by a small eye and resultant high hyperopia. It is frequently complicated by angle closure glaucoma, strabismus, amblyopia, and serous retinal and choroidal detachments. The pathogenesis of this condition is poorly understood, but genetic factors are thought to be a strong contributor. I have identified a novel human disease gene for familial nanophthalmos, myelin regulatory factor (MYRF), which also leads to retinal degeneration and retinal pigment epithelial (RPE) disruption in mice. This gene encodes a pleiotropic transcription factor and has been implicated in a multi-system disorder featuring cardiac, urogenital defects, and high hyperopia. The primary goals of my proposal are to: (i) identify the molecular targets of MYRF in the eye; (ii) define the mechanism by which disruption of MYRF leads to human disease and RPE dysfunction; and (iii) identify novel genetic contributors to the pathogenesis of high hyperopia. My over-arching hypothesis is that MYRF serves as a master regulator of RPE differentiation, and that disruption of key downstream targets of MYRF also leads to nanophthalmos by disrupting RPE structure and/or function. This hypothesis will be tested by: (i) determining the molecular targets of MYRF through single-cell RNA sequencing and CUT&RUN sequencing; and (ii) defining the clinical and genetic heterogeneity in families with high hyperopia and nanophthalmos. My long-term goal is to become an independent clinician investigator who focuses on identifying and treating inherited ocular disorders, and understanding molecular pathogenesis. To facilitate this goal, I have assembled a team of mentors and collaborators with relevant expertise; this team includes a developmental geneticist, an ophthalmology clinician-scientist, a medical geneticist, and an expert in genomics and bioinformatics. My mentors and I have developed a structured training plan focused on didactic and hands-on experience. Together with this team and a strong institutional environment, I will train in developmental biology, bioinformatics, and genomics, which are all required for my professional development and completion of this proposal. This career development trajectory will allow me to develop into a leading clinician-scientist in ophthalmic genetics, and provide a direct link between my clinical practice and my basic science research. It also will provide me with the skills to complete full cycles of gene discovery, which can have direct implications on patient care. This proposal will lead to insights into a novel pathway regulating RPE development and identify novel genes that regulate eye growth, which will establish a critical new area of future investigation.